Abcam, ab319036, Anti-KMT2B / MLL4 antibody [EPR27970-7] - C-terminal - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal KMT2B / MLL4 antibody. Carrier free. Suitable for Dot, WB, ChIP-seq and reacts with Recombinant fragment - Human, Human, Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR27970-7,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse, Rat,
Applications:Dot, ChIP-seq, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab319036 is the carrier-free version of
ab319035
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
KMT2B also known as MLL4 is a protein complex that functions as a histone methyltransferase. It specifically catalyzes the methylation of histone H3 on lysine 4 (H3K4) a modification associated with transcriptional activation. KMT2B has a molecular mass of approximately 296 kDa and is widely expressed in human tissues with notable expression in the brain heart and skeletal muscle. This protein is part of the COMPASS-like complexes which play significant roles in chromatin remodeling.
Biological function summary
KMT2B contributes to regulating gene expression. As part of the larger COMPASS-like complex it cooperates with other regulatory proteins to modify chromatin structure facilitating easier access of transcriptional machinery to DNA. This action influences the activation of genes important for cell differentiation and development. KMT2B interacts with several cofactors including WRAD components (WDR5 RBBP5 ASH2L and DPY30) enhancing its enzymatic activity.
Pathways
KMT2B functions prominently in signaling mechanisms like the Wnt and MAPK pathways. These pathways are integral to cell growth and differentiation. The protein intricately connects with other pathways’ proteins including beta-catenin in the Wnt pathway and ERK1/2 in the MAPK pathway. These interactions highlight KMT2B's role in regulating cellular functions and development.
KMT2B has associations with neurodevelopmental disorders and specific forms of cancer. Mutations in KMT2B can lead to dystonia a movement disorder characterized by involuntary muscle contractions. In cancer alterations affect pathways involving oncogenic factors such as MYC highlighting the critical connections between KMT2B and cellular growth regulation. Understanding these links provides insights into potential therapeutic targets for related conditions.